Expression and gene regulation network of EAF2 in cervical cancer based on data mining [post]

Wei na Kong, Fan Guo, Yang chun Feng, Jie Lv, Jia hui Fan, Yue Wang, Gang Zhao, Hui li Wu, Le Ai, Xiu min Ma
2020 unpublished
Background: ELL-associated factor 2 (EAF2) plays an important role in transcription elongation and the regulation of gene expression in both mammalian cells as well as in lower eukaryotes concurrent . EAF2's depletion has been demonstrated to enhance cell proliferation and greatly increase the risk of cancer. However, little is known about the expression and function of EAF2 in cervical cancer (CC) progression. Here, we comprehensively analyzed the expression of EAF2 and its clinical outcome in
more » ... clinical outcome in CC using publicly available cancer gene expression and patient survival data through various databases.Methods: We examined the differences of EAF2 expression between cancers and their normal tissues using the Oncomine, Gene expression Profiling Interactive Analysis 2 (GEPIA2), the Gene Expression across Normal and Tumor tissue 2 (GENT2) database and UALCAN databases. EAF2 expression was investigated from immunohistochemistry images using the Human Protein Atlas database. Copy number alterations (CNAs) and mutations of EAF2 were analyzed using cBioPortal. Kaplan–Meier analysis was used to predict the survival of EAF2 in CC. Analysis of the co-expression profile of EAF2 and the enrichment pathway of co-expression with EAF2 were revealed using LinkedOmics to explore the predicted signaling pathways. GeneMANIA visualize the gene networks and predict function of genes that GSEA identified as being enriched in CC: kinase LYN, mi-RNA133A, 133B and transcription factor OCT1. Results: We found that the expression of EAF2 decreased with the development of CC and significant upregulation of EAF2 is positively correlated with the overall survival (OS) of CC patients. The decrease of EAF2 gene expression may be partly due to promoter methylation and CNAs with the development of CC. Besides, EAF2 expression might be strongly positively correlated with the expression of IQCB1, ILDR1 and ASTE1, and may contribute to a signaling pathway in CC. Conclusion: Decreased EAF2 expression has negative clinical significance in the development of CC through the regulation of methylation, CNAs and related pathways. This suggests that EAF2 has potential as a therapeutic target for CC. Keywords: EAF2; cervical cancer; patient survival; clinical outcomes; cancer progression; multiomics analysis
doi:10.21203/rs.3.rs-35101/v1 fatcat:heos2vircrehtndzspkuj57ovq